top of page
CYTORA LOGO
News and Events banner.png

DATE:

TITLE:

ADDITIONAL FORMATS:

Circle-bg

9 April 2025

Cytora Reports Successful Results of Phase 1/2a Trial of Stem Cell Treatment for Diabetic Foot Ulcers

Read More

Listen to the podcast

Cytora bottom logo

Cytora’s patented platform technology is based on the discovery of a novel and unique stem cell population in the human oral mucosa (hOMSC), the origin of which is the embryonic nervous system. hOMSC are endowed with properties of neural crest, neural and mesenchymal stem cells. Cytora’s products are allogeneic, off-the-shelf, easily scalable, with a very competitive cost of goods (COG). The products were found to be safe and effective in early phase clinical trials in two indications: Diabetic Foot Ulcers (DFU) and Multiple System Atrophy (MSA).

Our products have high potential for treating complicated multifactorial diseases such as chronic and neurodegenerative diseases, incurable wounds and autoimmune diseases.

MENU

ABOUT US

TECHNOLOGY

PIPELINE

TEAM

PUBLICATIONS

CONTACT US

Dividing blue line

CONTACT US

info@cytorastem.com

© 2022 Cytora. All rights reserved.

bottom of page